ArticleJournal of neuro-oncology2009
Multifarious proteomic signatures and regional heterogeneity in glioblastomas.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.Neurosurgical review · 2014Pooled it
- Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapy.Theranostics · 2024Article
- Exploring glioblastoma stem cell heterogeneity: Immune microenvironment modulation and therapeutic opportunities.Frontiers in oncology · 2022Review
- AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses.Annals of translational medicine · 2021Article
- Review
- Cluster and Principal Component Analysis of Human Glioblastoma Multiforme (GBM) Tumor Proteome.Iranian journal of cancer prevention · 2014Article
- Recent advances in the molecular understanding of glioblastoma.Journal of neuro-oncology · 2012Review
- Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model.PloS one · 2012Article
- Proteomics of gliomas: initial biomarker discovery and evolution of technology.Neuro-oncology · 2011Review
- Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach.Proteome science · 2011Article
- Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.The Journal of clinical investigation · 2010Article
- Proteins inform survival-based differences in patients with glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the underlying intratumoral diversity of molecular profiles in glioblastomas, a proteomic approach was introduced to compare samples from regions of different histological grade. Using two-dimensional gel electrophoresis (2DE) with matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), we compared prospectively collected tissue samples of different histological grade areas of three glioblastoma patients. Consistent results showing relatively high expression of ubiquitin carboxyl-terminal esterase L1 in low-histological-grade areas (Grade 2 > Grades 3 and 4) and high expression of transthyretin in high-histological-grade areas (Grade 2 < Grades 3 and 4) were demonstrated. These results were confirmed by western blot (WB) analysis and immunohistochemical staining. This study provided the evidence of multifarious proteomic signatures according to regional and histological heterogeneity in glioblastomas.
Indexed as
Identifiers
19219580What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.